Washington, DC
April 1, 2004
First Report to Comprehensively Identify Issues and Outline a
Range of Options for Change
A range of options exists to enhance the
regulatory review process to address new challenges future
products of agricultural biotechnology are likely to present,
although opinions vary about the need for change, according to
Issues in the Regulation of Genetically Engineered Plants and
Animals, a new report released today by the
Pew Initiative on Food and
Biotechnology.
The report notes that current agricultural
biotechnology products have been widely adopted without evidence
of food safety or environmental problems, but the potential
complexity of future products may challenge the ability of the
existing Coordinated Framework for Regulation of Biotechnology
(administered by the Environmental Protection Agency (EPA), the
Food and Drug Administration (FDA), and the U.S. Department of
Agriculture (USDA)) to continue to protect public health and the
environment and maintain public trust. The report also examines
the extent to which agency regulatory practices are transparent,
clear, and open to public participation—all procedural elements
that will help build confidence in the integrity of the
regulatory system.
“The ability of the current regulatory review
system to keep pace with technology and manage the environmental
and food safety issues raised by future products has emerged as
an important part of the debate over agricultural
biotechnology,” noted Michael Rodemeyer, executive director of
the Pew Initiative on Food and Biotechnology. “By analyzing the
strengths and weaknesses of the Coordinated Framework’s ability
to address future products and identifying a range of options to
enhance the Framework, we hope to provide policymakers and
interested parties with a unique and valuable resource.”
While the report does not contain
recommendations, each chapter analyzes the current legal
authorities used by agencies to oversee a particular product,
examines the issues future products may raise for that review
process, discusses differing policy perspectives and outlines
policy options to address those issues. The report finds that:
* Both the EPA and USDA’s Animal and Plant
Health Inspection Service (APHIS) face challenges with respect
to their ability to manage possible environmental risks raised
by genetically engineered (GE) plants. APHIS may not have the
necessary regulations in place to: (1) comprehensively oversee
GE plants that cannot easily be defined as “plant pests”; (2)
consider broad environmental risks that may be posed by a GE
plant; or (3) quickly and fully manage environmental issues that
arise once the plant has been “deregulated” and entered the
marketplace. Similarly, current EPA regulations limit the
ability of the agency to enforce on-farm planting restrictions
developed to reduce the creation of insect resistance to
pesticides produced by some GE plants and to protect non-target
species. Finally, it appears that both APHIS and EPA have legal
authorities that could be used to regulate GE plants used to
produce industrial chemicals, but the agencies have not clearly
spelled out how or whether such authorities would be
coordinated. The report notes a number of options could be used
to address these issues, including clarifying the legal
authorities and policies of APHIS and EPA through administrative
rulings or legislation.
* FDA lacks the legal authority to require
developers to prove the safety of all foods derived from GE
plants—including imported foods--before they go to market, which
some believe is necessary. Others believe that FDA’s current
voluntary pre-market consultation program is sufficient to
ensure food safety. Additionally, it is unclear how agencies
would conduct an early food safety review to assess the
potential food safety risks if GE crops grown in experimental
field trials were to accidentally mix at low levels with crops
intended for the food supply. Options for addressing these
issues include using administrative rules to make pre-market
notification mandatory; requiring companies to obtain an
affirmative finding of safety from FDA before bringing a product
to market; and coordinating agency regulation to achieve
mandatory food safety review before a GE crop goes on the
market. Additional options, each involving various ranges of
administrative action and/or legislation, are also discussed.
* Federal agencies have not addressed how, or
if, they intend to regulate GE animals. The report states that
should FDA and/or USDA opt to exercise regulatory oversight of
GE animals, there are strengths and weaknesses associated with
the legal authorities the agencies are likely to invoke. If FDA
were to use the new animal drug provisions under the Food Drug
and Cosmetic Act (FDCA) to regulate GE animals, the agency would
have a significant level of pre- and post-market authority to
deal with food safety, animal health, and some environmental
issues related to GE animals, including a mandatory pre-market
review process that is currently absent for most GE plants.
However, the application of new animal drug approval provisions
to GE animals raises a number of issues, including a lack of
transparency and a question about FDA’s legal authority to
address the full range of environmental concerns associated with
GE animals. Alternatively, FDA could choose to regulate only the
food safety aspects of food derived from GE animals. While there
are a number of laws that USDA could use to regulate GE animals,
none appear to give USDA clear authority to address all of the
food safety, environmental and animal safety issues raised by GE
animals. Options noted in the report for dealing with these
issues include coordinating with other agencies to provide
environmental review or using legislation to clarify the
authorities of USDA or FDA to conduct more comprehensive reviews
of GE animals.
“There is no evidence that products now on the
market pose any food safety or environmental problems,”
concluded Rodemeyer. “But this report identifies areas where
regulators may not have adequate legal authority and the full
range of tools they need to address the complexities posed by
the next generation of products from agricultural biotechnology.
Going forward, policymakers will have to consider those issues
as well as the options available to improve the system.”
Biotechnology products have been regulated since
1986 according to the Coordinated Framework for Regulation of
Biotechnology, a federal policy that directs FDA, USDA and EPA
to coordinate the evaluation of biotech products using existing
laws including the Food, Drug and Cosmetic Act (FDCA), the
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and
the Toxic Substances Control Act (TSCA). The central premise of
the Coordinated Framework is that the process of biotechnology
itself poses no unique risks and that products engineered by
biotechnology should therefore be regulated under the same laws
as other products with similar compositions and intended uses.
In January 2004 the Animal Plant Health Inspection Service at
USDA announced it would prepare a programmatic environmental
impact statement for possible new regulations derived from the
Plant Protection Act, which was signed into law in 2000 and
could be a first significant step toward overhauling the
regulations APHIS uses to govern GE plants.
The Pew Initiative on Food and Biotechnology
is a nonprofit, nonpartisan research project whose goal is to
inform the public and policymakers on issues about genetically
modified food and agricultural biotechnology, including its
importance, as well as concerns about it and its regulation. It
is supported by a grant from The Pew Charitable Trusts to the
University of Richmond.
Preface
Crops
modified via modern biotechnology were first brought to market
in 1995 and have been widely embraced by
U.S.
farmers. Most of these “first generation” crops were designed to
help growers control weeds and agricultural pests. Today,
science is poised to bring the next generation of agricultural
biotechnology products to market. This next generation is likely
to involve more complex genetic engineering and a wider variety
of plants and animals. Some of these new products will continue
to help farmers control pests and weeds, but others will have
very different purposes, such as making foods with nutritional
benefits and using plants and animals to manufacture valuable
pharmaceutical and industrial substances.
When it
developed the regulatory framework for agricultural
biotechnology products in 1986, the federal government noted
that regulations should be reexamined periodically to ensure
that they were keeping pace with the technology. Since then, the
major federal regulatory agencies governing biotechnology—the
U.S. Department of Agriculture, the Food and Drug
Administration, and the Environmental Protection Agency—have all
issued regulations and/or guidance documents to address emerging
issues. But some observers question whether the existing
regulatory framework is adequate to address the issues likely to
be presented by the next generation of agricultural
biotechnology products. Others believe that the system is sound
and has sufficient flexibility to respond to any future needs.
In light of
the questions being raised by the rapid development of
agricultural biotechnology, and with the lessons of 18 years of
agricultural biotechnology regulation, the Pew Initiative on
Food and Biotechnology (PIFB) believes it is an appropriate time
to assess the regulatory framework. This report, prepared by the
staff of the PIFB, is an effort to capture the current debate
and the variety of perspectives that exist about the U.S.
regulatory system, and to make this information available to the
public and policy makers.
This report
draws on a variety of sources, including the public conferences
sponsored by the PIFB over the last several years and the
various experts who have contributed to reports published by the
organization. The report also draws on the substantial research
and analysis that was carried out on behalf of the PIFB’s
Stakeholder Forum on Agricultural Biotechnology, a group of
stakeholders from the business, agriculture, academic, and
public interest communities who met over the course of two years
to discuss the U.S. regulatory system for biotechnology. This
report represents solely the work of the PIFB staff, however,
and does not represent the views of the experts or Forum
members.
It is our
hope that this report will constructively contribute to the
ongoing public policy debate over agricultural biotechnology.
Michael
Rodemeyer
Executive Director
Pew Initiative on Food and Biotechnology
April 2004
Executive summary:
http://pewagbiotech.org/research/regulation/RegulationExecSum.pdf
Complete report:
http://pewagbiotech.org/research/regulation/Regulation.pdf
|